Bionano Genomics Files 8-K on Financials
Ticker: BNGO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, results-of-operations
Related Tickers: BNGO
TL;DR
BNGO filed an 8-K detailing financial results and exhibits. Keep an eye on their performance.
AI Summary
Bionano Genomics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's ongoing business activities and financial reporting requirements.
Why It Matters
This filing provides investors with crucial updates on Bionano Genomics' financial health and operational performance, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant changes in the company's risk profile.
Key Players & Entities
- Bionano Genomics, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38613 (identifier) — SEC File Number
- 26-1756290 (identifier) — IRS Employer Identification No.
- 9540 Towne Centre Drive, Suite 100 (address) — Principal Executive Offices
- San Diego, California 92121 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Bionano Genomics, Inc.?
The primary purpose is to report on the company's Results of Operations and Financial Condition, as well as to file Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported was on January 13, 2025.
In which U.S. state is Bionano Genomics, Inc. incorporated?
Bionano Genomics, Inc. is incorporated in Delaware.
What is the SEC file number for Bionano Genomics, Inc.?
The SEC file number for Bionano Genomics, Inc. is 001-38613.
What is the principal executive office address for Bionano Genomics, Inc.?
The principal executive office address is 9540 Towne Centre Drive, Suite 100, San Diego, California 92121.
Filing Stats: 1,153 words · 5 min read · ~4 pages · Grade level 15.6 · Accepted 2025-01-13 16:11:06
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Sto
Filing Documents
- bngo-20250113.htm (8-K) — 29KB
- bionano-q42024earningsprer.htm (EX-99.1) — 39KB
- image_2.jpg (GRAPHIC) — 45KB
- picture3a.jpg (GRAPHIC) — 3KB
- picture4a.jpg (GRAPHIC) — 2KB
- 0001411690-25-000003.txt ( ) — 268KB
- bngo-20250113.xsd (EX-101.SCH) — 2KB
- bngo-20250113_lab.xml (EX-101.LAB) — 21KB
- bngo-20250113_pre.xml (EX-101.PRE) — 12KB
- bngo-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Bionano Genomics, Inc. (the "Company") issued a press release reporting its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information provided in this Item 2.02 of this Current Report on Form 8-K shall be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and it shall be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K and accompany press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "could," "expected," "may," "potential," "will," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, fourth quarter 2024 revenue, potential impairments, write downs, and other non-cash or cash charges which may affect the Company's fourth quarter 2024 financial results and growth in the Company's core business; our ability to improve our margins, extend our cash runway and reach a potential pathway to profitability; our ability to execute on our strategy and achieve our objectives; the impact and utility of our cost savings initiative and our recent financing to position us for success in 2025; our ability to continue to drive OGM adoption by potential customers for routine use in genomic analysis; the impact, or lack thereof, of the Category I CPT code to accelerate or increase the adoption of OGM; continued research, presentations and publications involving OGM and its utility compared to traditional cytogenetics and our technologies; the impact of our Stratys system and VIA software to increase throughput and simplify analysis of OGM data; and our ability to drive adoption of OGM and our technology solutions; and our prospects for 2025. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include adjustments to our prelim
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued January 13, 2025, reporting preliminary financial results for the fourth quarter and fiscal year ended December 31, 2024 104 Inline XBRL for the cover page of this Current Report on Form 8-K
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: January 13, 2025 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive and Financial Officer)